Generali Asset Management SPA SGR Makes New $8.09 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Generali Asset Management SPA SGR bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,358 shares of the biopharmaceutical company's stock, valued at approximately $8,091,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. Amundi boosted its stake in Regeneron Pharmaceuticals by 45.8% in the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after acquiring an additional 487,489 shares during the last quarter. Proficio Capital Partners LLC lifted its stake in shares of Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after buying an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $127,489,000. Thrivent Financial for Lutherans lifted its stake in shares of Regeneron Pharmaceuticals by 1,272.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 125,194 shares of the biopharmaceutical company's stock valued at $89,179,000 after buying an additional 116,074 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of Regeneron Pharmaceuticals by 296.7% during the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock valued at $97,338,000 after buying an additional 102,198 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

REGN has been the topic of a number of recent research reports. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target on the stock. Citigroup dropped their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 4th. Finally, UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Trading Down 0.6 %

Shares of REGN stock traded down $4.14 on Friday, hitting $658.48. 1,869,108 shares of the company's stock traded hands, compared to its average volume of 633,035. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The company's fifty day simple moving average is $689.43 and its 200 day simple moving average is $818.17. The stock has a market capitalization of $71.99 billion, a price-to-earnings ratio of 17.20, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter last year, the firm earned $11.86 EPS. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.